Nama's AI scorecard currently rates Chemed Buy (7.0 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is CHE's P/E ratio?

Chemed trades at a trailing price-to-earnings ratio of 21.2.

When does CHE report earnings?

Chemed's next scheduled report is on Feb 24, 2027. Analysts expect EPS of $7.35.

What is the CHE price target?

The median analyst price target from 5 analysts is $620.00, with a range of $580.00 – $675.00.

Is CHE Shariah compliant?

Nama's AAOIFI-style screen reads Chemed as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.

Does CHE pay a dividend?

Yes — Chemed's dividend yield is 0.5%.

Nama Insights

Chemed (CHE)

Healthcare · Medical Care Facilities · NYSE

Chemed (CHE) is a Healthcare company in the Medical Care Facilities industry. It has a market capitalization of $6.84B, a trailing price-to-earnings ratio of 21.2 and a free-cash-flow yield of 4.3%. Over the most recent reported fiscal year, revenue grew 4.1% and free cash flow per share fell 7.1%. Nama's AI scorecard rates it Buy, 7.0 out of 10. On 12-month momentum it ranks in the rising band of its market.

AI scorecard

Buy · 7.0/10

Positive, at the low end of Buy. As of Nov 7, 2026.

Momentum

Rising · +16.5% over 12 months ex. last

Second-best fifth of its market on the past year's move.

Shariah screen

Shariah Compliant

Passes our debt, cash and income screen; not a scholar's ruling.

Off its high

-19.3%

How far the last close sits under the highest price of the past five years.

Market cap	$6.84B
Trailing P/E	21.2
Price / book	8.0
Price / sales	2.6
FCF yield	4.3%
Dividend yield	0.5%
Gross margin	32.4%
Operating margin	13.1%
Net margin	10.2%
Revenue growth (YoY)	+4.1%
Revenue growth (3-yr annual)	+5.8%
EPS growth (YoY)	-6.7%
FCF/share growth (YoY)	-7.1%
Beta	0.5
Exchange	NYSE
Sector	Healthcare
Industry	Medical Care Facilities

CHE earnings

Next report: Feb 24, 2027 (Q4 2026, EPS estimate $7.35). Beat the EPS estimate in 3 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Oct 27, 2026	$6.75	$6.44	+4.8%	$690.94M
Q2 2026	Jul 28, 2026	$6.06	$5.60	+8.2%	—
Q1 2026	Apr 23, 2026	$5.65	$5.30	+6.6%	$657.51M
Q4 2025	Feb 25, 2026	$6.42	$7.03	-8.7%	$639.34M

CHE analyst price target

Median target $620.00 from 5 analysts, ranging $580.00 – $675.00.

Medical Care Facilities peers

Ticker	Company	Market cap	P/E
HCA	HCA Healthcare	$103.40B	16.5
THC	Tenet Healthcare	$22.55B	12.7
EHC	Encompass Health	$13.50B	22.4
FMS	Fresenius Medical Care	$12.15B	10.2
DVA	DaVita	$12.04B	13.6
UHS	Universal Health Services	$11.52B	8.6
ENSG	Ensign Group	$10.56B	23.8
PACS	PACS Group	$7.87B	20.1

Explore live CHE data on Nama Insights →

Recent Congressional trades

Chemed trades disclosed by members of the US House and Senate under the STOCK Act. See the full Congress trades board →

Member	Chamber	Trade	Amount	Disclosed
Lisa McClain	House	Buy	$1,001 - $15,000	Aug 13, 2025
Byron Donalds	House	Sell	$1,001 - $15,000	Apr 14, 2025
Byron Donalds	House	Sell	$1,001 - $15,000	Apr 14, 2025

CHE FAQ

Is CHE a buy?: Nama's AI scorecard currently rates Chemed Buy (7.0 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is CHE's P/E ratio?: Chemed trades at a trailing price-to-earnings ratio of 21.2.
When does CHE report earnings?: Chemed's next scheduled report is on Feb 24, 2027. Analysts expect EPS of $7.35.
What is the CHE price target?: The median analyst price target from 5 analysts is $620.00, with a range of $580.00 – $675.00.
Is CHE Shariah compliant?: Nama's AAOIFI-style screen reads Chemed as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.
Does CHE pay a dividend?: Yes — Chemed's dividend yield is 0.5%.